A natural history model for planning prostate cancer testing

Calibration and validation using Swedish registry data

Andreas Karlsson, Alexandra Jauhiainen, Roman Gulati, Martin Eklund, Henrik Grönberg, Ruth Etzioni, Mark Clements

Research output: Contribution to journalArticle

Abstract

Recent prostate cancer screening trials have given conflicting results and it is unclear how to reduce prostate cancer mortality while minimising overdiagnosis and overtreatment. Prostate cancer testing is a partially observable process, and planning for testing requires either extrapolation from randomised controlled trials or, more flexibly, modelling of the cancer natural history. An existing US prostate cancer natural history model (Gulati et al, Biostatistics 2010;11:707-719) did not model for differences in survival between Gleason 6 and 7 cancers and predicted too few Gleason 7 cancers for contemporary Sweden. We re-implemented and re-calibrated the US model to Sweden. We extended the model to more finely describe the disease states, their time to biopsy-detectable cancer and prostate cancer survival. We first calibrated the model to the incidence rate ratio observed in the European Randomised Study of Screening for Prostate Cancer (ERSPC) together with age-specific cancer staging observed in the Stockholm PSA (prostate-specific antigen) and Biopsy Register; we then calibrated age-specific survival by disease states under contemporary testing and treatment using the Swedish National Prostate Cancer Register. After calibration, we were able to closely match observed prostate cancer incidence trends in Sweden. Assuming that patients detected at an earlier stage by screening receive a commensurate survival improvement, we find that the calibrated model replicates the observed mortality reduction in a simulation of ERSPC. Using the resulting model, we predicted incidence and mortality following the introduction of regular testing. Compared with a model of the current testing pattern, organised 8 yearly testing for men aged 55–69 years was predicted to reduce prostate cancer incidence by 14% and increase prostate cancer mortality by 2%. The model is open source and suitable for planning for effective prostate cancer screening into the future.

Original languageEnglish (US)
Article numbere0211918
JournalPloS one
Volume14
Issue number2
DOIs
StatePublished - Feb 1 2019
Externally publishedYes

Fingerprint

prostatic neoplasms
Natural History
natural history
Calibration
Registries
Prostatic Neoplasms
calibration
planning
Planning
Testing
Screening
testing
screening
Biopsy
neoplasms
Sweden
incidence
Survival
Mortality
Incidence

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Karlsson, A., Jauhiainen, A., Gulati, R., Eklund, M., Grönberg, H., Etzioni, R., & Clements, M. (2019). A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. PloS one, 14(2), [e0211918]. https://doi.org/10.1371/journal.pone.0211918

A natural history model for planning prostate cancer testing : Calibration and validation using Swedish registry data. / Karlsson, Andreas; Jauhiainen, Alexandra; Gulati, Roman; Eklund, Martin; Grönberg, Henrik; Etzioni, Ruth; Clements, Mark.

In: PloS one, Vol. 14, No. 2, e0211918, 01.02.2019.

Research output: Contribution to journalArticle

Karlsson, A, Jauhiainen, A, Gulati, R, Eklund, M, Grönberg, H, Etzioni, R & Clements, M 2019, 'A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data', PloS one, vol. 14, no. 2, e0211918. https://doi.org/10.1371/journal.pone.0211918
Karlsson, Andreas ; Jauhiainen, Alexandra ; Gulati, Roman ; Eklund, Martin ; Grönberg, Henrik ; Etzioni, Ruth ; Clements, Mark. / A natural history model for planning prostate cancer testing : Calibration and validation using Swedish registry data. In: PloS one. 2019 ; Vol. 14, No. 2.
@article{ff52b51d502b4fa3bd0ffc16bfc7c9e4,
title = "A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data",
abstract = "Recent prostate cancer screening trials have given conflicting results and it is unclear how to reduce prostate cancer mortality while minimising overdiagnosis and overtreatment. Prostate cancer testing is a partially observable process, and planning for testing requires either extrapolation from randomised controlled trials or, more flexibly, modelling of the cancer natural history. An existing US prostate cancer natural history model (Gulati et al, Biostatistics 2010;11:707-719) did not model for differences in survival between Gleason 6 and 7 cancers and predicted too few Gleason 7 cancers for contemporary Sweden. We re-implemented and re-calibrated the US model to Sweden. We extended the model to more finely describe the disease states, their time to biopsy-detectable cancer and prostate cancer survival. We first calibrated the model to the incidence rate ratio observed in the European Randomised Study of Screening for Prostate Cancer (ERSPC) together with age-specific cancer staging observed in the Stockholm PSA (prostate-specific antigen) and Biopsy Register; we then calibrated age-specific survival by disease states under contemporary testing and treatment using the Swedish National Prostate Cancer Register. After calibration, we were able to closely match observed prostate cancer incidence trends in Sweden. Assuming that patients detected at an earlier stage by screening receive a commensurate survival improvement, we find that the calibrated model replicates the observed mortality reduction in a simulation of ERSPC. Using the resulting model, we predicted incidence and mortality following the introduction of regular testing. Compared with a model of the current testing pattern, organised 8 yearly testing for men aged 55–69 years was predicted to reduce prostate cancer incidence by 14{\%} and increase prostate cancer mortality by 2{\%}. The model is open source and suitable for planning for effective prostate cancer screening into the future.",
author = "Andreas Karlsson and Alexandra Jauhiainen and Roman Gulati and Martin Eklund and Henrik Gr{\"o}nberg and Ruth Etzioni and Mark Clements",
year = "2019",
month = "2",
day = "1",
doi = "10.1371/journal.pone.0211918",
language = "English (US)",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - A natural history model for planning prostate cancer testing

T2 - Calibration and validation using Swedish registry data

AU - Karlsson, Andreas

AU - Jauhiainen, Alexandra

AU - Gulati, Roman

AU - Eklund, Martin

AU - Grönberg, Henrik

AU - Etzioni, Ruth

AU - Clements, Mark

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Recent prostate cancer screening trials have given conflicting results and it is unclear how to reduce prostate cancer mortality while minimising overdiagnosis and overtreatment. Prostate cancer testing is a partially observable process, and planning for testing requires either extrapolation from randomised controlled trials or, more flexibly, modelling of the cancer natural history. An existing US prostate cancer natural history model (Gulati et al, Biostatistics 2010;11:707-719) did not model for differences in survival between Gleason 6 and 7 cancers and predicted too few Gleason 7 cancers for contemporary Sweden. We re-implemented and re-calibrated the US model to Sweden. We extended the model to more finely describe the disease states, their time to biopsy-detectable cancer and prostate cancer survival. We first calibrated the model to the incidence rate ratio observed in the European Randomised Study of Screening for Prostate Cancer (ERSPC) together with age-specific cancer staging observed in the Stockholm PSA (prostate-specific antigen) and Biopsy Register; we then calibrated age-specific survival by disease states under contemporary testing and treatment using the Swedish National Prostate Cancer Register. After calibration, we were able to closely match observed prostate cancer incidence trends in Sweden. Assuming that patients detected at an earlier stage by screening receive a commensurate survival improvement, we find that the calibrated model replicates the observed mortality reduction in a simulation of ERSPC. Using the resulting model, we predicted incidence and mortality following the introduction of regular testing. Compared with a model of the current testing pattern, organised 8 yearly testing for men aged 55–69 years was predicted to reduce prostate cancer incidence by 14% and increase prostate cancer mortality by 2%. The model is open source and suitable for planning for effective prostate cancer screening into the future.

AB - Recent prostate cancer screening trials have given conflicting results and it is unclear how to reduce prostate cancer mortality while minimising overdiagnosis and overtreatment. Prostate cancer testing is a partially observable process, and planning for testing requires either extrapolation from randomised controlled trials or, more flexibly, modelling of the cancer natural history. An existing US prostate cancer natural history model (Gulati et al, Biostatistics 2010;11:707-719) did not model for differences in survival between Gleason 6 and 7 cancers and predicted too few Gleason 7 cancers for contemporary Sweden. We re-implemented and re-calibrated the US model to Sweden. We extended the model to more finely describe the disease states, their time to biopsy-detectable cancer and prostate cancer survival. We first calibrated the model to the incidence rate ratio observed in the European Randomised Study of Screening for Prostate Cancer (ERSPC) together with age-specific cancer staging observed in the Stockholm PSA (prostate-specific antigen) and Biopsy Register; we then calibrated age-specific survival by disease states under contemporary testing and treatment using the Swedish National Prostate Cancer Register. After calibration, we were able to closely match observed prostate cancer incidence trends in Sweden. Assuming that patients detected at an earlier stage by screening receive a commensurate survival improvement, we find that the calibrated model replicates the observed mortality reduction in a simulation of ERSPC. Using the resulting model, we predicted incidence and mortality following the introduction of regular testing. Compared with a model of the current testing pattern, organised 8 yearly testing for men aged 55–69 years was predicted to reduce prostate cancer incidence by 14% and increase prostate cancer mortality by 2%. The model is open source and suitable for planning for effective prostate cancer screening into the future.

UR - http://www.scopus.com/inward/record.url?scp=85061481204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061481204&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0211918

DO - 10.1371/journal.pone.0211918

M3 - Article

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0211918

ER -